Solid tumours, as cancer, continue to be one of the main diseases with the highest incidence worldwide, with therapeutic obstacles resulting from pharmacokinetic difficulties. The structural protein tubulin, essential for cell replication, acts as a validated drug target. However, issues such as resistance to treatment and adverse effects require improved therapeutic compounds. Digital modelling techniques, which encompass ligand–protein interaction analysis, atomic motion simulations, and 3D pharmacophore mapping, have transformed pharmaceutical research into drug design. These approaches predict molecular commitments in precise receptor regions (including binding pockets of taxoids and vinca alkaloids), refining molecular attraction and target specificity. Particle behaviour modelling assesses complex durability, while structure–activity correlation structures direct molecular refinements. Therefore, virtual protein structure analysis and in silico laboratory testing methodologies are essential for confirming possible treatments by targeting the drug to the region in the body that needs to be targeted.